Murine tumor necrosis factor alpha is transported from blood to brain in the mouse

The cytokines are important components of the brain-immune axis. Recent work has shown that [125I]IL-1 alpha and [125I]IL-1 beta are transported from the blood into the brain by a saturable system. Here we show that murine tumor necrosis factor alpha (mTNF alpha) labeled with 125I (I-mTNF alpha) crosses the blood-brain barrier (BBB) after i.v. injection by a transport system different from that for the interleukins. Self inhibition with mTNF alpha showed that this transport system was saturable, and lack of inhibition by IL-1 alpha, IL-1 beta, IL-6, or MIP-1 alpha showed selectivity of the system. High performance liquid chromatography (HPLC) of the radioactivity recovered from brain and from cerebrospinal fluid after the i.v. injection of I-mTNF alpha showed that the cytokine crossed the BBB largely in intact form. Capillary depletion showed that the accumulation of I-mTNF alpha in the cerebral cortex was due to passage across the BBB rather than to sequestration by capillaries. Transport rate was not changed by acute treatment with the neurotoxin aluminium or by acute and chronic treatment with the cationic chelator deferoxamine, but it was more than three times faster in neonatal rats. Efflux of I-mTNF alpha from the brain was slower than would have been predicted based on reabsorption of cerebrospinal fluid, suggesting that TNF alpha is sequestered by the brain. The BBB was not disrupted by up to 50 micrograms kg-1 of mTNF alpha i.v. in either adult mice or neonatal rats as assessed by the BBB's impermeability to radioactively labeled albumin.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  D. Greenblatt,et al.  Drug therapy. Clinical Pharmacokinetics (first of two parts). , 1975 .

[2]  W. Banks,et al.  Bidirectional transport of interleukin-1 alpha across the blood-brain barrier , 1989, Brain Research Bulletin.

[3]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  G. Soma,et al.  Biological activities of novel recombinant tumor necrosis factor having N-terminal amino acid sequences derived from cytotoxic factors produced by THP-1 cells. , 1988, Journal of Biological Response Modifiers.

[5]  W. Banks,et al.  Blood to brain transport of interleukin links the immune and central nervous systems. , 1991, Life sciences.

[6]  H. Besedovsky,et al.  Cytokines as modulators of the hypothalamus-pituitary-adrenal axis , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[7]  D. Ben-Nathan,et al.  Sodium dodecylsulphate induces a breach in the blood-brain barrier and enables a West Nile virus variant to penetrate into mouse brain , 1989, Brain Research.

[8]  R. L. Baldwin,et al.  Formation of ion-permeable channels by tumor necrosis factor-alpha. , 1992, Science.

[9]  R. Daynes,et al.  Neuropeptide regulation of inflammatory and immunologic responses. The capacity of alpha-melanocyte-stimulating hormone to inhibit tumor necrosis factor and IL-1-inducible biologic responses. , 1988, Journal of immunology.

[10]  T. Marunouchi,et al.  Production of tumor necrosis factor-alpha by microglia and astrocytes in culture , 1989, Brain Research.

[11]  N. Rothwell,et al.  Interleukin-6 is a centrally acting endogenous pyrogen in the rat. , 1991, Canadian journal of physiology and pharmacology.

[12]  H. Ikegami,et al.  Effect of TNF-alpha on prolactin secretion from rat anterior pituitary and dopamine release from the hypothalamus: comparison with the effect of interleukin-1 beta. , 1991, Endocrinologia japonica.

[13]  W. Banks,et al.  Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism. , 1991, The Journal of pharmacology and experimental therapeutics.

[14]  T. Kral,et al.  The immune-hypothalamic-pituitary-adrenal axis. , 1989, Endocrine reviews.

[15]  F. P. Nestel,et al.  Expression of tumor necrosis factor alpha in the developing nervous system. , 1991, The International journal of neuroscience.

[16]  P. Ricciardi-Castagnoli,et al.  Monokine production by microglial cell clones , 1989, European journal of immunology.

[17]  G. Nilaver,et al.  Immunoneurology: a serum protein afferent limb to the CNS. , 1990, Advances in experimental medicine and biology.

[18]  G. Pasternak,et al.  Mediation of anorexia by human recombinant tumor necrosis factor through a peripheral action in the rat. , 1989, Cancer research.

[19]  W. Banks,et al.  Inhibition of the brain to blood transport system for enkephalins and Tyr-MIF-1 in mice addicted or genetically predisposed to drinking ethanol. , 1989, Alcohol.

[20]  R. Merchant,et al.  Blood-brain barrier dysfunction in cats following recombinant interleukin-2 infusion. , 1987, Cancer research.

[21]  F. Sweep,et al.  Activation of the hypothalamus-pituitary-adrenal axis by cytokines. , 1991, Acta endocrinologica.

[22]  W. Fiers,et al.  Effects of tumor necrosis factor on prostacyclin production and the barrier function of human endothelial cell monolayers. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[23]  T. Fahey,et al.  Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia. , 1990, The Journal of clinical investigation.

[24]  W. Banks,et al.  The interleukins-1α, -1β, and -2 do not acutely disrupt the murine blood - brain barrier , 1992 .

[25]  T. Watanabe,et al.  Characteristics of fever and acute-phase response induced in rabbits by IL-1 and TNF. , 1989, The American journal of physiology.

[26]  V. Diehl,et al.  Phase I study of 24-hour continuous intravenous infusion of recombinant human tumor necrosis factor. , 1988, Journal of biological response modifiers.

[27]  W. Pardridge,et al.  Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma Proteins , 1990, Journal of neurochemistry.

[28]  C. Ábrahám,et al.  Recombinant human tumor necrosis factor α constricts pial arterioles and increases blood-brain barrier permeability in newborn piglets , 1992, Neuroscience Letters.

[29]  W. Banks,et al.  Aluminum-Induced neurotoxicity: Alterations in membrane function at the blood-brain barrier , 1989, Neuroscience & Biobehavioral Reviews.

[30]  P. Triozzi,et al.  Central Nervous System Toxicity of Biological Response Modifiers , 1990, Annals of the New York Academy of Sciences.

[31]  J. Connor,et al.  Receptor‐mediated transcytosis of transferrin across the blood‐brain barrier , 1987, Journal of neuroscience research.

[32]  C. Plata-salamán,et al.  Tumor necrosis factor and interleukin-1β: suppression of food intake by direct action in the central nervous system , 1988, Brain Research.

[33]  C. Sweep,et al.  Cytokines and the hypothalamic-pituitary-adrenal axis , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[34]  G. Pasternak,et al.  Identification and characterization of receptors for tumor necrosis factor-α in the brain , 1991 .

[35]  J. M. Mullin,et al.  Effect of tumor necrosis factor on epithelial tight junctions and transepithelial permeability. , 1990, Cancer research.

[36]  A. R. Sherman,et al.  Iron deficiency and interleukin 1 production by rat leukocytes. , 1987, The American journal of clinical nutrition.

[37]  D. Scarborough Cytokine Modulation of Pituitary Hormone Secretion a , 1990, Annals of the New York Academy of Sciences.

[38]  W. Banks,et al.  Chapter 21: Bidirectional passage of peptides across the blood-brain barrier , 1992 .

[39]  Ronald G. Blasberg,et al.  Transport of α-Aminoisobutyric Acid across Brain Capillary and Cellular Membranes , 1983 .

[40]  P. Peterson,et al.  Tumor Necrosis Factor-α is a Potent ACTH Secretagogue: Comparison to Interleukin-1β , 1989 .

[41]  B. Storer,et al.  Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. , 1991, Cancer research.

[42]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[43]  E. O. Johnson,et al.  Interactions between tumor necrosis factor-alpha, hypothalamic corticotropin-releasing hormone, and adrenocorticotropin secretion in the rat. , 1990, Endocrinology.

[44]  Y. Shimada,et al.  Tumor necrosis factor reduces lifespan of human endothelial cells in vitro , 1990, Mechanisms of Ageing and Development.